Home News and Events Press Release
Press Release
You can learn about a more comprehensive Argo Biopharma through the latest information.
You can learn about a more comprehensive Argo Biopharma through the latest information.
You can learn about a more comprehensive Argo Biopharma through the latest information.
First Patient Dosed in Phase 2 Clinical Trial of Argo Biopharma BW-01, a Novel siRNA Drug for the Treatment of Severe Hypertriglyceridemia
Learn MoreArgo Biopharma has completed phase 1 clinical trials for BW-01, a siRNA candidate for cardiovascular diseases, in China and Australia.
Learn MoreShanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis.
Learn MoreArgo Biopharma closed series A+ financing of over 40 milion US dollars led by CS Capital.
Learn MoreArgo Biopharma’s first siRNA drug approved for clinical study in China, the United States, and Australia.
Learn MoreArgo Biopharma’s second siRNA drug approved for clinical study in Australia.
Learn MoreArgo Biopharma’s first siRNA drug approved for clinical study in Australia.
Learn More
为了更好的呈现效果，移动端请竖屏浏览
